Drug data last refreshed 16h ago · AI intelligence enriched 19h ago
Reserpine is an oral tablet small molecule antihypertensive agent approved in 1955 by Novartis. It is an alkaloid derived from Rauwolfia serpentina that works as a monoamine depleter, reducing sympathetic nervous system activity to lower blood pressure. The drug is now primarily used for hypertension management in patients who may benefit from older, well-characterized agents.
As a 70-year-old product approaching loss of exclusivity with minimal commercial activity, this brand supports a small, maintenance-focused team with limited growth opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on reserpine offers minimal career upside; the product has no active job openings and serves primarily as a legacy product requiring compliance and regulatory stewardship. This role is suitable only for professionals seeking stability in a mature, low-visibility therapeutic area or those building regulatory expertise in historical drug management.
Worked on RESERPINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.